We are live on
!
Find out more
ESPR
Esperion Therapeutics
ESPR
ESPR
Delisted
ESPR was delisted on the 10th of July, 2026.
150 hedge funds and large institutions have $1.21B invested in Esperion Therapeutics in 2017 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 54 increasing their positions, 45 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
154% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 13
23% more capital invested
Capital invested by funds: $987M → $1.21B (+$224M)
20% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 45
15% more funds holding
Funds holding: 131 → 150 (+19)
0.7% less ownership
Funds ownership: 94.73% → 94.04% (-0.7%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
46% less call options, than puts
Call options by funds: $23M | Put options by funds: $42.8M
Holders
150
Holders Change
+19
Holders Change %
+14.5%
% of All Funds
3.74%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.15%
New
33
Increased
54
Reduced
45
Closed
13
Calls
$23M
Puts
$42.8M
Net Calls
-$19.8M
Net Calls Change
+$53.8M
Top Buyers
Top Sellers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$33.9M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$24.1M |
| 3 |
State Street
Boston,
Massachusetts
|
-$11.9M |
| 4 |
PC
Paulson & Co
New York
|
-$9.74M |
| 5 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$8.78M |
